SCHEMBL27168516

SCHEMBL27168516

O=[N+]([O-])c1cccc(C2=CCOCC2)c1CCF

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 3/20 0.34
▸ S100A4 P26447 2/20 0.33
▸ MAPT P10636 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ RECQL P46063 1/20 0.33
▸ MCL1 Q07820 1/20 0.33
▸ RXFP1 Q9HBX9 1/20 0.33
▸ PTPRC P08575 1/20 0.31
▸ PDCD1 Q15116 1/20 0.31
▸ CD274 Q9NZQ7 1/20 0.31
▸ TDP1 Q9NUW8 5/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ IDH2 P48735 1/20 0.31
▸ GPR35 Q9HC97 1/20 0.30
▸ PKM P14618 1/20 0.30
▸ CSNK1D P48730 1/20 0.30
▸ CSNK1E P49674 1/20 0.30
▸ POLB P06746 1/20 0.30
▸ ATM Q13315 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27168546 0.88 MAPK14 (0.34) MAPK14S100A4MAPTKMT2ARECQL
SCHEMBL29516860 0.81 S100A4 (0.37) MAPK14S100A4MAPTKMT2ARECQL
SCHEMBL25529496 0.81 S100A4 (0.37) MAPK14S100A4MAPTKMT2ARECQL
SCHEMBL27168535 0.75 MAPK14 (0.34) MAPK14S100A4MAPTKMT2ARECQL
SCHEMBL26162646 0.75 MAPK14 (0.34) MAPK14S100A4MAPTKMT2ARECQL
SCHEMBL26162618 0.75 MAPT (0.39) MAPK14MAPTKMT2ARECQLMCL1
SCHEMBL25197753 0.74 IDH2 (0.36) MAPK14RECQLTDP1ALDH1A1IDH2
SCHEMBL29517002 0.74 IDH2 (0.36) MAPK14RECQLTDP1ALDH1A1IDH2
SCHEMBL29162256 0.73 MAPK14 (0.33) MAPK14S100A4MAPTKMT2ARECQL
SCHEMBL26162637 0.72 MAPK14 (0.36) MAPK14S100A4MAPTKMT2ARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12421217-B2 Pyrazine derivative or salt thereof, and use of same FUJIFILM CORPORATION (JP) 2025-09-23 — — US disclosed
EP-4052760-B1 PYRAZINE DERIVATIVE OR SALT THEREOF, AND USE OF SAME FUJIFILM CORP (JP) 2024-03-13 — — EP disclosed
EP-4052760-A1 PYRAZINE DERIVATIVE OR SALT THEREOF, AND USE OF SAME FUJIFILM Corporation (JP) 2022-09-07 — — EP disclosed
US-20220259185-A1 PYRAZINE DERIVATIVE OR SALT THEREOF, AND USE OF SAME FUJIFILM CORPORATION (JP) 2022-08-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12421217-B2 Pyrazine derivative or salt thereof, and use of same DHODH, IDH1, IDH2 MAPK14 2456/4885S100A4 4163/4885MAPT 4437/4885
US-20220259185-A1 PYRAZINE DERIVATIVE OR SALT THEREOF, AND USE OF SAME DHODH, IDH1, IDH2 MAPK14 2456/4885S100A4 4163/4885MAPT 4437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback